Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
12 Cards in this Set
- Front
- Back
|
Intergroup 0099: Null hypothesis
|
Intergroup 0099: Null hypothesis
In patients with stage III and IV nasopharyngeal cancer, there is no difference in survival with radiotherapy versus chemoradiotherapy. |
|
|
Intergroup 0099: Who was included?
|
Intergroup 0099: Who was included?
Patients with biopsy-proven stage III and IV nasopharyngeal carcinoma without evidence of systemic mets (M0) or prior RT and no plan for resection other than persistent neck nodes after completion of therapy. |
|
|
Intergroup 0099: Treatment volume
|
Intergroup 0099: Treatment volume
Primary tumor site and neck nodes to the clavicle Upper neck field: nasopharynx and upper neck - Two opposed laterals - Included base of skull and sphenoid sinus - Post: 2 cm beyond mastoid process with 1.5 cm beyond palpable nodal disease - Ant: posterior third of maxillary sinus and nasal cavity - Inf: thyroid notch |
|
|
Intergroup 0099: Dose
|
Intergroup 0099: Dose
Primary + 2cm margin: 70 Gy Nodes > 2cm: 70 Gy Nodes < 2cm: 66 Gy N0: 50 Gy |
|
|
Intergroup 0099: Randomization
|
Intergroup 0099: Randomization
Radiotherapy alone Chemoradiotherapy --> more chemo |
|
|
Intergroup 0099: Chemotherapy
|
Intergroup 0099: Chemotherapy
Concurrent with RT - Cisplatin 100 mg/m2 on days 1, 22, and 43 Post-RT - Cisplatin 80 mg/m2 days 71, 99, and 127 - 5FU 1000 mg/m2/d CI x 96h days 71-74, 99-102, and 127-130 starting four weeks after RT |
|
|
Intergroup 0099: Primary endpoints
|
Intergroup 0099: Primary endpoints
PFS OS |
|
|
Intergroup 0099: Results
|
Intergroup 0099: Results
PFS - RT: 15m - CCRT: Not reached - 3yr PFS: RT 24% CCRT 69% OS - Mean OS RT: 34m - CCRT: Not reached - 3yr survival: RT 47% CCRT 78% |
|
|
Intergroup 0099: Reported overall 5-year survival for nasopharyngeal carcinoma
|
Intergroup 0099: Previously reported overall 5-year survival for nasopharyngeal carcinoma
41% |
|
|
Intergroup 0099: Why was the survival rate for patients in the radiotherapy arm higher than expected?
|
Intergroup 0099: Why was the survival rate for patients in the radiotherapy arm higher than expected?
May be due to salvage rate of these patients after disease progression or recurrence. |
|
|
Do women with node-negative breast cancers 5 cm and larger require postmastectomy RT?
|
Floyd IJROBP 2006 66 358
- Retrospective 70 patients - Mastectomy without RT - 5-year LRF 7.6% - 5-year OS 83% and DFS 86% - LVI increased risk so RT Taghian JCO 2006 24 3927 - 313 NSABP mastectomy patients - 10-year LRF 7.1% - With or without chemotherapy |
|
|
In young women with DCIS status post lumpectomy, is a boost necessary?
|
Omlin Lancet Oncol 2006 7 652
- 373 women with TisN0 - Age <= 45 years with BCT - 57 no RT, 166 no boost, 150 with boost - Medial follow-up 72 months - 10-year LRF survival (p < 0.0001) -- No RT: 46% -- RT no boost: 72% -- RT with boost: 86% - 10-year OS 97% (no diff) For women <= 45 years with DCIS, boost improves local control. |
